Twenty-three of 26 adults with obesity who entered a Wegovy trial with excess fat in their livers had normal liver fat levels by week 72, Novo Nordisk said in a press release on its semaglutide liver fat analysis issued Oct. 1. The findings were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy.
That works out to 88.5%, the "9 out of 10" figure in Novo's headline. But it comes from a small subgroup of a much larger trial program, and Novo describes the work as a post hoc, exploratory analysis that was not a pre-specified primary or secondary goal of the trials.
